SAB BIOTHERAPEUTICS, INC. Gain (Loss) on Termination of Lease
SAB BIOTHERAPEUTICS, INC. (SABS) reported Gain (Loss) on Termination of Lease of $7.04 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2026-05-12
- SAB BIOTHERAPEUTICS, INC. gain (loss) on termination of lease for the quarter ending 2026-03-31 was $7.04K.
- SAB BIOTHERAPEUTICS, INC. gain (loss) on termination of lease for fiscal 2022 was $32.21K.
- SAB BIOTHERAPEUTICS, INC. gain (loss) on termination of lease for fiscal 2021 was $0.00.
| Period end | Gain (Loss) on Termination of Lease 3 month | Gain (Loss) on Termination of Lease 12 month |
|---|---|---|
| 2026-03-31 | $7.04K 10-Q · filed 2026-05-12 | |
| 2022-12-31 | $32.21K 10-K · filed 2024-03-29 | |
| 2021-12-31 | $0.00 10-K · filed 2023-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |